Witnessing the stock’s movement on the chart, on Wednesday, Xilio Therapeutics Inc (NASDAQ: XLO) set off with pace as it heaved 38.38% to $1.37, before settling in for the price of $0.99 at the close. Taking a more long-term approach, XLO posted a 52-week range of $0.49-$2.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 0.00%. Meanwhile, its Annual Earning per share during the time was -44.91%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 54.80%. This publicly-traded company’s shares outstanding now amounts to $27.61 million, simultaneously with a float of $19.83 million. The organization now has a market capitalization sitting at $60.21 million. At the time of writing, stock’s 50-day Moving Average stood at $0.8305, while the 200-day Moving Average is $0.8985.
Xilio Therapeutics Inc (XLO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Xilio Therapeutics Inc’s current insider ownership accounts for 54.89%, in contrast to 14.59% institutional ownership. According to the most recent insider trade that took place on Apr 02 ’24, this organization’s 10% Owner bought 485,250 shares at the rate of 0.76, making the entire transaction reach 368,790 in total value, affecting insider ownership by 7,345,473. Preceding that transaction, on Feb 08 ’24, Company’s 10% Owner sold 733 for 0.64, making the whole transaction’s value amount to 469. This particular insider is now the holder of 2,019,563 in total.
Xilio Therapeutics Inc (XLO) Earnings and Revenue Records
Xilio Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 54.80% and is forecasted to reach -0.58 in the upcoming year.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Let’s observe the current performance indicators for Xilio Therapeutics Inc (XLO). It’s Quick Ratio in the last reported quarter now stands at 2.02. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 25.51.
In the same vein, XLO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.11, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -0.58 at the market close of one year from today.
Technical Analysis of Xilio Therapeutics Inc (XLO)
Going through the that latest performance of [Xilio Therapeutics Inc, XLO]. Its last 5-days volume of 0.84 million indicated improvement to the volume of 0.54 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 85.13% While, its Average True Range was 0.1332.
Raw Stochastic average of Xilio Therapeutics Inc (XLO) in the period of the previous 100 days is set at 95.83%, which indicates a major rise in contrast to 95.52% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 160.46% that was higher than 90.81% volatility it exhibited in the past 100-days period.
